Abstract
Background and Aims: Bempedoic acid (an ATP citrate lyase inhibitor) has recently been licensed for the treatment of dyslipidaemia in patients who are intolerant of statins. We aimed to assess if the tolerability and efficacy seen in clinical trials could be replicated in statin-intolerant patients in routine clinical practice.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
